Tests docetaxel chemotherapy after radiotherapy for high-risk prostate cancer
Studies whether extra docetaxel chemotherapy after radiotherapy helps men with high-grade prostate cancer.
Plain-language title generated from the registry record
Registry title: Adjuvant Chemotherapy for High Malignant Prostate Cancer
Key facts
- Where
- Baoding, Beijing, and Shenzhen, ChinaSee the 3 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with prostate cancer that is confirmed by biopsy or surgery, is high grade, and has not spread to distant parts of the body. It tests docetaxel chemotherapy after radical treatment.
- Age
- 18 to 80 years
- Sex
- Men only
- Disease stage
- Prostate cancer with a Gleason score of 9-10 (GG grade 5) or with Gleason 5 components, and no sign of distant spread on imaging.
- Earlier treatment
- The person is expected to have standard radical treatment or radiotherapy after surgery. No earlier radiotherapy to the abdomen.
Main reasons for not taking part
- Another cancer in the past, unless it was fully treated more than 5 years ago
- Earlier radiotherapy to the abdomen
- Weight loss of more than 10% in the past 6 months
- Bleeding disorders or active infection
- Significant heart or blood vessel disease, or a condition that makes chemotherapy too hard to tolerate
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06864533, who can take part
Where in China
- Hebei Yi Zhou Cancer HospitalBaoding, ChinaContact: Chao LiuTaking people
- Peking University First HospitalBeijing, ChinaContact: Mingwei MaTaking people
- Peking University Shenzhen HospitalShenzhen, ChinaContact: Yajie LiuTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Peking University First Hospital
- Trial code
- NCT06864533
- Record updated
- 20 August 2026
- Original description
This study aims to evaluate the efficacy of adjuvant docetaxel chemotherapy following radical radiotherapy in patients with localized high-grade prostate cancer. Eligible participants include those diagnosed with prostate cancer confirmed by biopsy or surgical pathology, with a Gleason score of 9-10 or containing a Gleason 5 component, and no evidence of distant metastasis. Patients will be divided into two groups: the standard treatment group receiving only radical treatment (radiotherapy or surgery), and the standard treatment plus chemotherapy group, receiving four to six cycles of docetaxel chemotherapy after standard treatment. The primary endpoint is Failure-Free Survival (FFS), with secondary endpoints including Biochemical Relapse-Free Survival (BRFS), Metastasis-Free Survival (MFS), Overall Survival (OS), and assessment of adverse events The study aims to better understand the impact of adjuvant chemotherapy on the prognosis of patients with high-risk prostate cancer and determine whether it improves survival outcomes.Read full original descriptionShow less
Evaluation of Chemotherapy With Adjuvant Docetaxel After Radiotherapy for Localized High Malignant Prostate Cancer: A Prospective Muti-center Non-Randomized Controlled Trial
This study aims to evaluate the efficacy of adjuvant docetaxel chemotherapy following radical radiotherapy in patients with localized high-grade prostate cancer. Eligible participants include those diagnosed with prostate cancer confirmed by biopsy or surgical pathology, with a Gleason score of 9-10 or containing a Gleason 5 component, and no evidence of distant metastasis. Patients will be divided into two groups: the standard treatment group receiving only radical treatment (radiotherapy or surgery), and the standard treatment plus chemotherapy group, receiving four to six cycles of docetaxel chemotherapy after standard treatment. The primary endpoint is Failure-Free Survival (FFS), with secondary endpoints including Biochemical Relapse-Free Survival (BRFS), Metastasis-Free Survival (MFS), Overall Survival (OS), and assessment of adverse events The study aims to better understand the impact of adjuvant chemotherapy on the prognosis of patients with high-risk prostate cancer and determine whether it improves survival outcomes.
Inclusion: Histologically confirmed prostate cancer diagnosed by biopsy or surgery with a Gleason score of 9-10 (GG grade 5) or containing Gleason 5 components; No evidence of distant metastasis confirmed by imaging; Expected to receive standard radical treatment or postoperative radiotherapy; Estimated survival time greater than 12 months; Aged ≥ 18 years; Karnofsky Performance Status (KPS) ≥ 80; Adequate blood count: white blood cell ≥ 3.5 × 10\^9/L, neutrophils ≥ 1.5 × 10\^9/L, platelets ≥ 100.0 × 10\^.
Exclusion: Previous abdominal radiation therapy; Pre-existing or concomitant bleeding disorders; History of malignant tumors (except those cured for more than 5 years); Active infections; Significant cardiovascular disease (e.g., controlled hypertension, unstable angina, NYHA class ≥ II congestive heart failure, unstable symptomatic arrhythmias, or ≥ II peripheral vascular disease) or any condition deemed intolerable to chemotherapy by the oncology department; Weight loss > 10% within the past 6 months.